Barclays PLC Ardelyx, Inc. Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Barclays PLC holds 728,642 shares of ARDX stock, worth $4.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

728,642

Previous 892,707 18.38%

Holding current value

$4.28 Million

Previous $3.5 Million 14.98%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	SELL	$3.92 - $6.64 $643,134 - $1.09 Million	-164,065 Reduced 18.38%	728,642 $4.02 Million
Q2 2025 Aug 13, 2025	BUY	$3.28 - $5.51 $1.47 Million - $2.48 Million	449,467 Added 101.4%	892,707 $3.5 Million
Q1 2025 May 15, 2025	SELL	$4.91 - $6.36 $439,022 - $568,673	-89,414 Reduced 16.79%	443,240 $2.18 Million
Q4 2024 Feb 13, 2025	SELL	$4.49 - $6.85 $65,872 - $100,496	-14,671 Reduced 2.68%	532,654 $2.7 Million
Q3 2024 Nov 15, 2024	BUY	$5.28 - $7.57 $577,024 - $827,287	109,285 Added 24.95%	547,325 $3.77 Million

Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $125,032 - $197,632	-21,228 Reduced 4.62%	438,040 $3.25 Million
Q1 2024 May 15, 2024	SELL	$6.05 - $9.74 $10.4 Million - $16.8 Million	-1,726,352 Reduced 78.99%	459,268 $3.35 Million
Q4 2023 Feb 15, 2024	BUY	$3.29 - $6.64 $955,063 - $1.93 Million	290,293 Added 15.32%	2,185,620 $13.6 Million
Q3 2023 Nov 07, 2023	BUY	$3.3 - $4.83 $3.02 Million - $4.42 Million	915,971 Added 93.53%	1,895,327 $7.73 Million
Q2 2023 Aug 03, 2023	BUY	$3.23 - $4.95 $1.61 Million - $2.47 Million	498,094 Added 103.5%	979,356 $3.32 Million
Q1 2023 May 04, 2023	BUY	$2.68 - $4.79 $1.29 Million - $2.31 Million	481,262 New	481,262 $2.31 Million
Q2 2022 Aug 12, 2022	SELL	$0.51 - $1.17 $7,999 - $18,352	-15,686 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $66,040 - $119,889	-101,601 Reduced 86.63%	15,686 $17,000
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $68,860 - $136,119	80,070 Added 215.14%	117,287 $129,000
Q3 2021 Nov 09, 2021	BUY	$1.27 - $8.17 $32,172 - $206,970	25,333 Added 213.17%	37,217 $49,000
Q2 2021 Aug 13, 2021	SELL	$6.55 - $8.98 $333,047 - $456,606	-50,847 Reduced 81.06%	11,884 $90,000
Q1 2021 May 13, 2021	BUY	$6.1 - $7.69 $218,904 - $275,963	35,886 Added 133.68%	62,731 $415,000
Q4 2020 Feb 11, 2021	SELL	$5.05 - $7.1 $33,400 - $46,959	-6,614 Reduced 19.77%	26,845 $174,000
Q3 2020 Nov 12, 2020	SELL	$5.25 - $7.08 $42,372 - $57,142	-8,071 Reduced 19.43%	33,459 $176,000
Q2 2020 Aug 12, 2020	BUY	$5.37 - $8.11 $109,972 - $166,084	20,479 Added 97.28%	41,530 $289,000
Q1 2020 May 13, 2020	SELL	$4.35 - $8.79 $118,315 - $239,079	-27,199 Reduced 56.37%	21,051 $119,000
Q4 2019 Feb 10, 2020	BUY	$4.23 - $8.29 $102,437 - $200,758	24,217 Added 100.77%	48,250 $362,000
Q3 2019 Nov 14, 2019	SELL	$2.15 - $6.28 $16,036 - $46,842	-7,459 Reduced 23.69%	24,033 $113,000
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $44,815 - $67,132	17,998 Added 133.38%	31,492 $85,000
Q1 2019 May 15, 2019	BUY	$1.88 - $3.35 $22,772 - $40,578	12,113 Added 877.12%	13,494 $38,000
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $62,696 - $157,119	-37,769 Reduced 96.47%	1,381 $2,000
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $70,818 - $87,815	18,885 Added 93.19%	39,150 $170,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $46,079 - $72,233	12,454 Added 159.44%	20,265 $75,000
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $12,690 - $19,852	2,513 Added 47.43%	7,811 $39,000
Q4 2017 Feb 14, 2018	SELL	$4.85 - $7.8 $111,084 - $178,651	-22,904 Reduced 81.21%	5,298 $35,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $122,678 - $160,751	28,202	28,202 $158,000

Others Institutions Holding ARDX

# of Institutions

245

Shares Held

161M

Call Options Held

697K

Put Options Held

1.61M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $908M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account